annual cash & cash equivalents:
$319.59M+$130.93M(+69.40%)Summary
- As of today (August 4, 2025), ACAD annual cash & cash equivalents is $319.59 million, with the most recent change of +$130.93 million (+69.40%) on December 31, 2024.
- During the last 3 years, ACAD annual cash & cash equivalents has risen by +$172.15 million (+116.77%).
- ACAD annual cash & cash equivalents is now -1.97% below its all-time high of $326.03 million, reached on December 31, 2020.
Performance
ACAD Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$217.70M-$101.89M(-31.88%)Summary
- As of today (August 4, 2025), ACAD quarterly cash & cash equivalents is $217.70 million, with the most recent change of -$101.89 million (-31.88%) on March 31, 2025.
- Over the past year, ACAD quarterly cash & cash equivalents has increased by +$12.95 million (+6.33%).
- ACAD quarterly cash & cash equivalents is now -51.87% below its all-time high of $452.35 million, reached on September 30, 2020.
Performance
ACAD quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ACAD Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +69.4% | +6.3% |
| 3 y3 years | +116.8% | +6.2% |
| 5 y5 years | +68.5% | +25.8% |
ACAD Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +178.3% | -31.9% | +121.7% |
| 5 y | 5-year | -2.0% | +178.3% | -51.9% | +130.0% |
| alltime | all time | -2.0% | +7076.0% | -51.9% | +4884.0% |
ACAD Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $217.70M(-31.9%) |
| Dec 2024 | $319.59M(+69.4%) | $319.59M(+106.0%) |
| Sep 2024 | - | $155.15M(-12.4%) |
| Jun 2024 | - | $177.13M(-13.5%) |
| Mar 2024 | - | $204.75M(+8.5%) |
| Dec 2023 | $188.66M(+64.3%) | $188.66M(+92.1%) |
| Sep 2023 | - | $98.19M(-9.0%) |
| Jun 2023 | - | $107.94M(-62.9%) |
| Mar 2023 | - | $290.89M(+153.3%) |
| Dec 2022 | $114.85M(-22.1%) | $114.85M(-25.8%) |
| Sep 2022 | - | $154.84M(+10.7%) |
| Jun 2022 | - | $139.83M(-31.8%) |
| Mar 2022 | - | $204.92M(+39.0%) |
| Dec 2021 | $147.44M(-54.8%) | $147.44M(+55.8%) |
| Sep 2021 | - | $94.64M(-64.5%) |
| Jun 2021 | - | $266.96M(-12.3%) |
| Mar 2021 | - | $304.49M(-6.6%) |
| Dec 2020 | $326.03M(+71.9%) | $326.03M(-27.9%) |
| Sep 2020 | - | $452.35M(+45.7%) |
| Jun 2020 | - | $310.44M(+79.4%) |
| Mar 2020 | - | $173.06M(-8.8%) |
| Dec 2019 | $189.68M(+40.8%) | $189.68M(-50.8%) |
| Sep 2019 | - | $385.47M(+417.9%) |
| Jun 2019 | - | $74.43M(-23.7%) |
| Mar 2019 | - | $97.56M(-27.6%) |
| Dec 2018 | $134.76M(+94.1%) | $134.76M(+110.9%) |
| Sep 2018 | - | $63.90M(-13.9%) |
| Jun 2018 | - | $74.18M(-36.2%) |
| Mar 2018 | - | $116.33M(+67.6%) |
| Dec 2017 | $69.42M(-57.6%) | $69.42M(-38.4%) |
| Sep 2017 | - | $112.62M(-21.7%) |
| Jun 2017 | - | $143.79M(-8.6%) |
| Mar 2017 | - | $157.38M(-3.8%) |
| Dec 2016 | $163.62M(+60.2%) | $163.62M(+6.5%) |
| Sep 2016 | - | $153.68M(+16.6%) |
| Jun 2016 | - | $131.77M(-24.8%) |
| Mar 2016 | - | $175.22M(+71.6%) |
| Dec 2015 | $102.14M(+65.1%) | $102.14M(+44.3%) |
| Sep 2015 | - | $70.80M(-24.0%) |
| Jun 2015 | - | $93.21M(+22.0%) |
| Mar 2015 | - | $76.42M(+23.6%) |
| Dec 2014 | $61.85M | $61.85M(+70.1%) |
| Sep 2014 | - | $36.37M(+165.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $13.70M(-85.8%) |
| Mar 2014 | - | $96.45M(+723.9%) |
| Dec 2013 | $11.71M(-79.8%) | $11.71M(-0.8%) |
| Sep 2013 | - | $11.80M(-51.3%) |
| Jun 2013 | - | $24.25M(+31.5%) |
| Mar 2013 | - | $18.44M(-68.2%) |
| Dec 2012 | $57.90M(+740.5%) | $57.90M(+622.3%) |
| Sep 2012 | - | $8.02M(-12.9%) |
| Jun 2012 | - | $9.21M(+65.7%) |
| Mar 2012 | - | $5.56M(-19.3%) |
| Dec 2011 | $6.89M(+0.6%) | $6.89M(-17.2%) |
| Sep 2011 | - | $8.32M(+3.7%) |
| Jun 2011 | - | $8.02M(+17.4%) |
| Mar 2011 | - | $6.83M(-0.3%) |
| Dec 2010 | $6.85M(-62.2%) | $6.85M(-29.1%) |
| Sep 2010 | - | $9.66M(+9.6%) |
| Jun 2010 | - | $8.81M(-51.2%) |
| Mar 2010 | - | $18.07M(-0.3%) |
| Dec 2009 | $18.12M(-14.4%) | $18.12M(+4.6%) |
| Sep 2009 | - | $17.32M(-3.7%) |
| Jun 2009 | - | $17.98M(-4.5%) |
| Mar 2009 | - | $18.84M(-11.0%) |
| Dec 2008 | $21.17M(+24.6%) | $21.17M(-4.7%) |
| Sep 2008 | - | $22.21M(+9.5%) |
| Jun 2008 | - | $20.29M(-3.4%) |
| Mar 2008 | - | $21.00M(+23.7%) |
| Dec 2007 | $16.99M(+9.7%) | $16.99M(-27.6%) |
| Sep 2007 | - | $23.46M(-40.8%) |
| Jun 2007 | - | $39.63M(+77.6%) |
| Mar 2007 | - | $22.32M(+44.2%) |
| Dec 2006 | $15.48M(+58.0%) | $15.48M(-41.0%) |
| Sep 2006 | - | $26.23M(-31.7%) |
| Jun 2006 | - | $38.42M(+241.1%) |
| Mar 2006 | - | $11.26M(+15.0%) |
| Dec 2005 | $9.80M(+18.0%) | $9.80M(-58.1%) |
| Sep 2005 | - | $23.35M(+47.7%) |
| Jun 2005 | - | $15.81M(+40.7%) |
| Mar 2005 | - | $11.24M(+35.3%) |
| Dec 2004 | $8.30M(+31.6%) | $8.30M(+45.8%) |
| Sep 2004 | - | $5.69M(-30.2%) |
| Jun 2004 | - | $8.16M(+86.7%) |
| Mar 2004 | - | $4.37M(-30.8%) |
| Dec 2003 | $6.31M(+41.6%) | $6.31M |
| Dec 2002 | $4.45M | - |
FAQ
- What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
- What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
- What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
- What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ACAD is $319.59M
What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. all-time high annual cash & cash equivalents is $326.03M
What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ACAD annual cash & cash equivalents has changed by +$130.93M (+69.40%)
What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ACAD is $217.70M
What is the all time high quarterly cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. all-time high quarterly cash & cash equivalents is $452.35M
What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ACAD quarterly cash & cash equivalents has changed by +$12.95M (+6.33%)